On this Psychedelics Exclusive podcast, we’re talked about the psychedelic industry with the Chief Visionary Officer at Psycheceutical, Mike ‘Zappy’ Zapolin. Ever the optimist about when the science is leading, Mr. Zapolin imparts his thoughts following his attendance at the Benzinga Cannabis Capital Conference in Miami.
Off the opening segment, Zappy talks about the anticipation of what comes next following a discussion that Dr. Matthew Johnson gave at the Conference which garnered some attention:
“You know, Dr. Matthew Johnson From Johns Hopkins, he is the number one scientist in the psychedelic space. So for him to sit down and gives us all the, you know, session on what’s happening with the science and the data—it was so positive that I think everyone there was like, ‘Wow, like, this is coming from Matthew Johnson,’ saying how favorable the MAPS stuff is, how significant it’s going to be for, you know, COMPASS Pathways to commercialize.”
Matthew W. Johnson is a well-known psychedelic drug researcher and a professor of psychiatry and behavioral sciences at Johns Hopkins University School of Medicine. He has conducted extensive research on the use of psychedelics, such as psilocybin, LSD, and DMT, for therapeutic and spiritual purposes. JHU is world renowned as a foremost leader in the research of psychedelic medicine, and Dr. Johnson is a sought-after SME throughout the world.
Johnson has been involved in various studies investigating the therapeutic potential of psychedelic drugs, including psilocybin-assisted therapy for depression and anxiety, smoking cessation, and end-of-life anxiety in cancer patients. He has also conducted research on the safety of these substances and the potential risks associated with their use.
Zappy Zapolin had much more to say, in his characteristic upbeat and enthusiastic method of delivery.
To view our previous Psychedelics Exclusive podcast featuring MindMed CEO Robert Barrow, click here.